Related Experiment Video
Updated: Jun 14, 2026

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Harmonization and integration of pharmacogenomics screens
Aleysha T Chen1, Marcus R Kelly2,3, Trey Ideker1,2,3,4
1Department of Bioengineering, University of California, San Diego, San Diego, CA 92093, United States.
Motivation:
Large pharmacogenomics screens have generated a wealth of information cataloguing the responses of more than a thousand tumor cell-line models to FDA-approved and exploratory drugs. Although centralized repositories have consolidated data access, the diversity of experimental platforms and response metrics used in these screens have made it challenging to integrate and compare their measured drug responses. Towards better pharmacogenomic data harmonization, we surveyed a range of data analysis protocols based on different curve-fitting functions (sigmoid, piecewise linear), different response metrics (IC50, EC50, integrated AUC), and different drug concentration windows (full range or truncated).
Results:
We found that an AUC derived from a sigmoidal curve fitted to a truncated dose range yields the strongest agreement between screening platforms, significantly bettering other protocols surveyed. This harmonization procedure also best aligns drug responses across successive iterations of the same platform. These findings broadly inform efforts to integrate drug response data in large-scale analyses.
Availability:
The source code to generate drug response profiles and correlations are available at https://github.com/digitaltumors/Pharmacogenomics_Screens_Harmonization.git.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Metabolism: Overview
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

